Margaret H. Collins, MD
- Staff Pathologist, Division of Pathology
- Director, GI Pathology
- Professor, UC Department of Pathology and Laboratory Medicine
- UC Department of Pediatrics
- margaret.collins@cchmc.org
- Board Certified
About
Biography
I belong to a community of researchers at Cincinnati Children’s Hospital Medical Center, plus other institutions here and abroad, who are unwaveringly committed to finding cures for pediatric gastrointestinal (GI) diseases, including eosinophilic gastrointestinal disorders (EGID). This is especially important to me after meeting patients and their caregivers, witnessing the impact that EGID has on their lives and sharing their hope for a Food and Drug Administration (FDA)-approved therapy.
My research strives to improve diagnostic methods for children with GI diseases, such as EGID and inflammatory bowel disease. As a pediatric pathologist at Cincinnati Children’s, I help evaluate the efficacy of various therapies, including biologics, for pediatric patients who have EGID. I also participate in multi-institutional studies of pediatric inflammatory bowel disease.
I helped create the eosinophilic esophagitis histology scoring system (EoEHSS), which systematically evaluates esophageal biopsies obtained for eosinophilic esophagitis, the most common form of EGID. Some of the features evaluated correlate with symptoms and potentially provide new therapeutic endpoints.
Beginning in 2011, U.S. News & World Report named me one of the Top Doctors in Pathology. In 2020, I received the American Academy of Asthma, Allergy and Immunology (AAAAI) and American Partnership for Eosinophilic Disorders (APFED) award for the best EGID abstract at the AAAAI annual meeting.
BS: Fordham University, NY, 1972
MD: Georgetown University, Washington D.C., 1977
Residency: Pathology, New York Hospital, NY, 1977-1980
Residency: Pathology, Columbia-Presbyterian Medical Center, NY, 1980-1983
Fellowship: Research, New York Lung Association, Columbia-Presbyterian Medical Center, NY, 1983-85
Fellowship: Research, American Lung Association, Columbia-Presbyterian Medical Center, NY, 1985-87
Certifications: Pathology, 1981; Pediatric Pathology, 1991
Interests
Pediatric gastrointestinal pathology; eosinophilic gastrointestinal diseases; biopsy analyses; primary study endpoints; novel therapies to treat eosinophilic esophagitis in children; disorders of bowel immunity; bowel motility disorders
Services and Specialties
Research Areas
Publications
Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. The Lancet Gastroenterology and Hepatology. 2026.
Tissue remodeling in eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2026.
Molecular Characterization of Non-Specific Esophagitis Reveals a Distinct Non-Eosinophilic Phenotype With Fibrotic Traits. Allergy. European Journal of Allergy and Clinical Immunology. 2026.
Tu1096 CORRELATING THE EOSINOPHILIC ESOPHAGITIS HISTOLOGY SCORING SYSTEM (EOEHSS) WITH PEAK ESOPHAGEAL EOSINOPHIL COUNTS: POOLED RESULTS FROM EOE KIDS AND LIBERTY EOE TREET. Gastrointestinal Endoscopy. 2026; 103(5):s-814-s-815.
Tu1096 CORRELATING THE EOSINOPHILIC ESOPHAGITIS HISTOLOGY SCORING SYSTEM (EOEHSS) WITH PEAK ESOPHAGEAL EOSINOPHIL COUNTS: POOLED RESULTS FROM EOE KIDS AND LIBERTY EOE TREET. Gastroenterology. 2026; 170(6):s-814-s-815.
Automated Eosinophil Quantification Using Deep Learning to Predict Therapy Escalation in Pediatric Ulcerative Colitis. Clinical and Translational Gastroenterology. 2026.
Dupilumab normalizes the eosinophilic esophagitis disease transcriptome. Journal of Allergy and Clinical Immunology. 2026.
Peripheral blood markers of pediatric eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2026; 157(4):1002-1005.
Peripheral blood markers of eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2026; 157(2):ab62.
Implications of Model Loss and Configuration for Sparse Histological Segmentation. In: Machine Learning Methods in Biomedical Field. Springer Nature; 2026:189-217.
From the Blog
Tale of Two Studies Shows Mixed Progress Against EoE
Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD6/26/2024
After 1 Year, Weekly Doses of Dupilumab Most Effective at Managing Eosinophilic Esophagitis
Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD8/31/2023
Biological Agent Successfully Treats Eosinophilic Esophagitis
Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD12/22/2022
Artificial Intelligence Holds the Key to Diagnosing Rare Esophageal Food Allergy Disease
Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD10/25/2021
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey